Artificial intelligence is increasingly becoming a powerful tool in medical research, and a new personalised cancer vaccine developed by Moderna and Merck has brought that potential into sharper focus.
The companies have announced positive Phase 3 trial results for intismeran autogene, an experimental personalised mRNA vaccine designed for patients with high-risk melanoma whose tumours have been surgically removed.
The treatment is being studied in combination with Merck's immunotherapy drug Keytruda. More than 1,000 melanoma patients were involved in the trial, which examined whether the personalised treatment could help reduce the risk of the cancer returning or spreading.
The development also drew reactions from prominent figures, including US President Donald Trump and Elon Musk. Musk argued that advances in mRNA and artificial intelligence could increasingly turn the discovery and development of treatments into what he described as a “software problem.”
How AI Helps Create a Personalised Cancer Vaccine
Unlike conventional treatments designed for large groups of patients, personalised cancer vaccines are created using the unique genetic characteristics of an individual's tumour.
The process begins after a patient's tumour is removed and genetically sequenced. Tumours can contain hundreds of mutations, but not all of them are equally useful for training the immune system to recognise cancer cells.
This is where AI and automated computational systems play an important role.
The technology analyses mutations found in the tumour and identifies those most likely to trigger an immune response. Scientists can then select up to 34 tumour-specific targets, known as neoantigens, for inclusion in the personalised mRNA vaccine.
The mRNA carries instructions that allow the patient's cells to produce proteins linked to those cancer-specific mutations. The immune system can then learn to recognise these markers and potentially attack cancer cells carrying them.
In simple terms, AI helps researchers narrow down a vast number of tumour mutations and identify the most promising targets for an individual patient's vaccine.
What Is Intismeran Autogene?
Intismeran autogene is a personalised mRNA cancer vaccine being developed by Moderna and Merck.
Unlike a preventive vaccine, it is designed as a therapeutic cancer treatment for people who have already been diagnosed with melanoma.
The vaccine is intended to work alongside Keytruda, an immunotherapy drug that helps the immune system detect and attack cancer cells.
The goal is to create a treatment specifically tailored to the genetic fingerprint of each patient's tumour rather than relying on a one-size-fits-all approach.
Phase 3 Trial Shows Positive Results
The Phase 3 study focused on patients with high-risk melanoma who had undergone surgery to remove their tumours.
According to the companies, the personalised vaccine and Keytruda combination showed positive results in reducing the risk of melanoma recurrence or spread compared with Keytruda alone.
The findings could be significant because melanoma can return even after surgery, particularly among patients with advanced or high-risk disease.
Moderna and Merck are expected to present the data at a scientific meeting and discuss potential regulatory submissions for the treatment.
However, the vaccine is still subject to regulatory review before it can become widely available to patients.
Elon Musk Says Curing Diseases Is Becoming a ‘Software Problem’
The development attracted attention from Elon Musk, who argued that mRNA technology and artificial intelligence could fundamentally change how new treatments are developed.
Musk suggested that artificial RNA could make it possible to design treatments in a way that increasingly resembles solving complex computational problems.
His comments reflect a broader debate within the technology and healthcare sectors about whether AI can significantly accelerate drug discovery, disease research and personalised medicine.
Several AI industry leaders have also predicted that artificial intelligence could play a major role in tackling diseases over the coming years. However, experts continue to stress that AI-generated discoveries must still undergo extensive laboratory testing, clinical trials and regulatory evaluation.
Why This Could Be a Major Moment for Cancer Treatment
Personalised cancer vaccines represent a different approach from traditional chemotherapy.
Chemotherapy can affect both cancerous and healthy cells, often leading to significant side effects. A personalised mRNA vaccine, meanwhile, aims to train the immune system to recognise specific features associated with a patient's cancer.
The potential advantage is precision.
Instead of treating every patient with the same therapy, scientists can analyse an individual's tumour and develop a treatment based on its unique mutations.
If successful on a wider scale and approved by regulators, this approach could eventually influence how several types of cancer are treated.
For now, the Moderna-Merck trial represents one of the most significant developments in personalised mRNA cancer treatment, while also highlighting how AI is increasingly being used to analyse complex biological data and accelerate the development of new therapies.
